Persistent inflammatory reaction at the injection site of II-2 with lymphoma-like inflammatory infiltrates;Persistierende knotige Lokalreaktion mit Lymphomähnlichen Infiltraten nach s.c-injektion von interleukin-2

Hautarzt

Volumn 53, Issue 8, 2002, Pages 554-557

  Assmann, K ^a   Nashan, D ^a   Grabbe, S ^a   Luger, T A ^a   Metze, D ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Adverse drug effect; Interleukin 2; Local reaction; Melanoma

Indexed keywords

RECOMBINANT INTERLEUKIN 2; CD30 ANTIGEN; DRUG DERIVATIVE; INTERLEUKIN 2; RECOMBINANT PROTEIN;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CASE REPORT; HISTIOCYTE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATORY INFILTRATE; MELANOMA; METASTASIS; PANNICULITIS; SKIN CANCER; TREATMENT OUTCOME; AGED; CHEMICALLY INDUCED DISORDER; CUTANEOUS T CELL LYMPHOMA; DRUG EFFECT; DRUG ERUPTION; ENZYME IMMUNOASSAY; FEMALE; PALLIATIVE THERAPY; PATHOLOGY; SKIN; SKIN TUMOR; SUBCUTANEOUS DRUG ADMINISTRATION;

AGED; ANTIGENS, CD30; DRUG ERUPTIONS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN-2; LYMPHOMA, T-CELL, CUTANEOUS; MELANOMA; NEOPLASM METASTASIS; PALLIATIVE CARE; PANNICULITIS; RECOMBINANT PROTEINS; SKIN; SKIN NEOPLASMS;

EID: 0036882247     PISSN: 00178470     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00105-001-0305-9     Document Type: Article

References (17)

1. Elgart GW, Sheremata W, Ahn YS (1997) Cutaneous reactions to recombinant human interferon beta-1b: The clinical and histologic spectrum. J Am Acad Dermatol 37:553-558
2. Gaspari AA, Lotze MT, Rosenberg SA, Stern JB, Katz SI (1987) Dermatologic changes associated with intreleukin 2 administration. JAMA 258:1624-1629
3. Grimm EA, Mazumder A, Zhang HZ et al. (1982) The lymphokine-activated cell phenomenon: lysis of NK-resistant fresh solid tumor cells by IL-2-activated autologous human peripheral blood lymphocytes. J Exp Med 155:1823-1841
4. Grimm EA, Ramsey KM, Mazumder A et al. (1983) Lymphokine-activated cell phenomenon. II. The precursor phenotype is serologically distinct from peripheral T lymphocytes, memory CTL, and NK cells. J Exp Med 157:884-97
5. Grimm EA, Robb RJ, Roth JA et al. (1983) Lymphokine-activated killer cell (LAK) phenomenon. III. Evidence that IL-2 alone is sufficient for direct activation of PBL into LAK. J Exp Med 158:1356-1361
6. Hefeneider SH, Conlon PJ, Henney CS et al. (1983) In vivo interleukin-2 administration augments the generation of alloreactive cytolytic T lymphocytes and resident natural killer cells. J Immunol 130:222-227
7. Klapholz L, Ackerstein A, Goldenhersch MA, Vardy D, Nagler A (1993) Local cutaneous reaction induced by subcutaneous interleukin-2 and interferon alpha-2a immunotherapy following ABMT. Bone Marrow Transplant 11:443-446
8. Lee RE, Gaspari AA, Lotze MT et al. (1988) Interleukin-2 and psoriasis. Arch Dermatol 124:1811-1815
9. McElrath MJ, Kaplan G, Burkhardt RA, Cohn ZA (1990) Cutaneous response to recombinant interleukin 2 in human immunodeficiency virus 1-seropositive individuals. PNAS 87:5783-5787
10. Morgan DA, Ruscetti FW, Gallo R (1976) Selective in vitro growth of T-lymphocytes from normal human bone marrows. Science 193:1007-1008
11. Okaneya T, Ogawa A (1991) Induction of cytotoxicity of the renal hilar lymph nodes by pedal subcutaneous administration of interleukin-2 in patients with renal cancer. Cancer 67:1332-1337
12. Reinhold U, Hausschild A (1997) Einsatz von Interleukin-2 und supportive Therapie des malignen Melanoms. Dermatologische Onkologie. Garbe C, Dummer R, Kaufmann R, Tilgen W (Hrsg) Springer, Heidelberg Berlin New York Tokyo
13. Rosenberg SA, Lotze MT, Muul LM et al. (1985) Observations in the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313:1485-1492
14. Smith KA (1998) Interleukin-2: inception, impact, and implications. Science 240:1169-1176
15. Taniguchi T, Matsui H, Fujita T et al. (1983) Structure and expression of cloned cDNA for human interleukin-2. Nature 302:305-307
16. West WH, Tauer KW, Yanneli JR, Marshall GD, Orr DW, Thurmann GB, Oldham RK (1987) Constant-infusion of recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 316:898-905
17. Wolkenstein P, Chosidow O, Revuz J et al. (1993) Cutaneous side effects associated with interleukin-2 administration for metastatic melanoma. J Am Acad Dermatol 28:66-70